A practical reference on lipolysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-13 and is reviewed periodically as new material appears.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) Psilocin (4-hydroxy-N,N-dimethyltryptamine) Baeocystin (4-phosphoryloxy-N-methyltryptamine) Norbaeocystin (4-phosphoryloxytryptamine) Aeruginascin (N,N,N-trimethyl-4-phosphoryloxytryptamine) The potential psychoactivity of other compounds other than psilocybin and psilocin has been speculated but not confirmed. The concentrations of psilocin and psilocybin, as determined by high-performance liquid chromatography, are in the range of 0.14–0.42% (wet weight) and 0.37–1.30% (dry weight) in the whole mushroom 0.17–0.78% (wet weight) and 0.44–1.35% (dry weight) in the cap, and 0.09%–0.30% (wet weight) and 0.05–1.27% (dry weight) in the stem, respectively. For quickly and practically measuring the psychoactive contents of most healthy Psilocybe cubensis varieties, it can generally be assumed that there is approximately 15 mg (± 5 mg) of psilocybin per gram of dried mushroom. Furthermore, due to factors such as age and storage method, the psilocybin and psilocin content of a given sample of mushrooms will vary. Individual body composition, brain chemistry and psychological predisposition play a significant role in determining appropriate doses. For a modest psychedelic effect, a minimum of one gram of dried Psilocybe cubensis mushrooms is ingested orally, 0.25–1 gram is usually sufficient to produce a mild effect, 1–2.5 grams usually provides a moderate effect and 2.5 grams and higher usually produces strong effects.
==== 2011–2018: Rebuilding, return of trophies, and departure ==== Wenger's preparations for the 2011–12 season were disrupted by player unrest. Though he insisted none of his top players would leave the club, Fàbregas eventually moved to Barcelona, while Gaël Clichy and Samir Nasri joined Manchester City. Suspensions and injuries left Wenger fielding an understrength side against Manchester United on 29 August 2011; Arsenal were trounced 8–2, which represented their worst defeat in 115 years. Needing to address the squad's lack of depth, Wenger completed a series of deals in the final days of the summer transfer window. He mostly brought in experienced players, such as Yossi Benayoun on loan from Chelsea, Everton's Mikel Arteta and Germany international Per Mertesacker. By October, Arsenal had made their worst start to a season in 58 years, losing four of their opening seven matches. However, the team soon harmonised and, in the same month, club captain Robin van Persie scored a hat-trick as Arsenal beat Chelsea 5–3. Despite another season of no silverware, Wenger guided Arsenal to third position in the Premier League, thus qualifying for the Champions League for a 15th successive campaign. Van Persie had scored 37 goals, in his first injury-free season for the club. He, however, grew disillusioned with Arsenal's transfer policy, and decided not to renew his contract, with one year remaining. When Manchester United manager Sir Alex Ferguson learnt of the situation, he called Wenger to push through a deal and Van Persie agreed to join Manchester United in August 2012.
=== Post-World War II period === The federation and football overall was disrupted by World War II. After the war, a socialist federation was formed and the football federation reconstituted. It was one of the founding members of the UEFA in 1954.
The suffix -thiol is added to the name of the alkane. This method is nearly identical to naming an alcohol and is used by the IUPAC, e.g. CH3SH would be methanethiol. The word mercaptan replaces alcohol in the name of the equivalent alcohol compound. Example: CH3SH would be methyl mercaptan, just as CH3OH is called methyl alcohol. The term sulfhydryl- or mercapto- is used as a prefix, e.g. mercaptopurine.
Sources: en.wikipedia.org
== Low-energy CID and high-energy CID == Low-energy CID is typically carried out with ion kinetic energies less than approximately 1 kiloelectron volt (1 keV). Low-energy CID is highly efficient in fragmenting the selected precursor ions, but the type of fragment ions observed in low-energy CID is strongly dependent on the ion kinetic energy. Very low collision energies favor ion structure rearrangement, and the probability of direct bond cleavage increases as ion kinetic energy increases, leading to higher ion internal energies. High-energy CID (HECID) is carried out in magnetic sector mass spectrometers or tandem magnetic sector mass spectrometers and in tandem time-of-flight mass spectrometers (TOF/TOF). High-energy CID involves ion kinetic energies in the kilovolt range (typically 1 keV to 20 keV). High-energy CID can produce some types of fragment ions that are not formed in low-energy CID, such as charge-remote fragmentation in molecules with hydrocarbon substructures or sidechain fragmentation in peptides.
== Sports == F2 Logistics is also involved in sports. It formerly owned the F2 Logistics Cargo Movers, a women's volleyball team active from 2016 to 2023. It competed in the Philippine Super Liga and Premier Volleyball League. It also sponsors the La Salle women's volleyball team and the Parañaque Patriots basketball team of the Maharlika Pilipinas Basketball League.
Muslims, India's largest religious minority, have contributed significantly to a synthetic Indo-Islamic religious culture. Sufism, the heterodox mystical movement in Islam found receptiveness among adherents of the medieval regional Shaivite and Vaishnavite traditions of Bhakti. Sikh gurdwaras and Sufi dargahs often attract both visitors and worshippers from other religions. India has monastic traditions such as that of Jain ascetics some of whom practice an extreme form of nonviolence (ahimsa) and Buddhist communities that have preserved ancient styles of meditations. This religious diversity coexists with religious endogamy—people rarely marry outside their faith. There is also religious segregation in housing—religious groups cluster by choice or necessity. Thus, India's religious picture has both rich intermixing and clear divisions.
Sources: en.wikipedia.org
=== Glycoprotein VI (GPVI) === Glycoprotein VI is one of the immunoglobulin superfamily type I transmembrane glycoproteins. It is an important collagen receptor involved in collagen-induced platelet activation and adhesion. It plays a key role in their procoagulant activity and subsequent thrombin and fibrin formation. Its procoagulant function may contribute to arterial or venous thrombosis. The FCR pathway of GPVI activation involves γ chain (GPVI transmembrane domain associates with γ chain FCR), Src kinase FYN / LYN, and LAT adaptor protein, all participating in phospholipase C activation.
=== Fibronectin glomerulopathy === Fibronectin glomerulopathy is a rare form of glomerulopathy characterised by enlarged glomeruli with deposits in the mesangium and subendothelial space. The deposits have been shown to be fibronectin. This condition is inherited in an autosomal dominant fashion. About 40% of cases are due to mutations in the fibronectin (FN1) gene located on chromosome 2 (2q34).
Collagen alpha-5(VI) chain also known as von Willebrand factor A domain-containing protein 4 is a protein that in humans is encoded by the COL6A5 gene. COL6A5 is a part of the Collagen VI gene family which produce collagen components for the Extracellular matrix of most connective tissues. In the human genome, part of the collagen VI family is located on chromosome 3q in order of COL6A4, COL6A5, COL6A6. Transcription of COL6A5 only occurs in skin, lung, testis, colon, and small intestine cells.
== Clinical significance == Mutations in the COL3A1 gene cause vascular Ehlers-Danlos syndrome (vEDS; OMIM 130050), classified under this name in the 2017 International Classification of the Ehlers–Danlos Syndromes and formerly designated EDS type IV. It is the most severe form of EDS, since patients often die suddenly due to rupture of large arteries or other hollow organs. A few patients with arterial aneurysms without clear signs of EDS have also been found to have COL3A1 mutations. More recently, mutations in COL3A1 have also been identified in patients with severe brain anomalies suggesting that type III collagen is important for the normal development of the brain during embryogenesis. This phenotype resembles the cortical malformation caused by loss-of-function mutations in ADGRG1 (formerly GPR56; OMIM 604110), the gene encoding adhesion G protein-coupled receptor G1. Type III collagen is a known ligand for this receptor, linking the finding to a shared brain-development pathway. The first single base mutation in the COL3A1 gene was reported in 1989 in a patient with vEDS and changed a glycine amino acid to a serine Since then, more than 600 different variants have been reported in the COL3A1 gene. About 2/3 of these mutations change a glycine amino acid to another amino acid in the triple-helical region of the protein chain. A large number of RNA splicing mutations have also been identified.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.